These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 1532323)
1. Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy? Dundee JW; McMillan CM; Yang J; Wright PM Br J Clin Pharmacol; 1992 Feb; 33(2):200-1. PubMed ID: 1532323 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the P6 antiemetic point, in patients having highly emetic cytotoxic drugs. McMillan C; Dundee JW; Abram WP Br J Cancer; 1991 Nov; 64(5):971-2. PubMed ID: 1834156 [No Abstract] [Full Text] [Related]
3. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054 [TBL] [Abstract][Full Text] [Related]
4. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist. Egan AP; Taggart JR; Bender CM Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124 [TBL] [Abstract][Full Text] [Related]
5. Management of nausea and vomiting caused by anticancer drugs: state of the art. Pisters KM; Kris MG Oncology (Williston Park); 1992 Feb; 6(2 Suppl):99-104. PubMed ID: 1532744 [TBL] [Abstract][Full Text] [Related]
7. [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs]. Sampi K; Taguchi T Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):922-8. PubMed ID: 2140498 [TBL] [Abstract][Full Text] [Related]
8. [Prophylaxis of chemotherapy-induced vomiting and nausea]. Tóth J; Szántó J Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468 [TBL] [Abstract][Full Text] [Related]
9. Ondansetron, a new antiemetic therapy for oncology. An overview. Lip H Scand J Gastroenterol Suppl; 1990; 178():55-61. PubMed ID: 2148983 [TBL] [Abstract][Full Text] [Related]
10. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F). Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R Oncology; 1991; 48(5):403-5. PubMed ID: 1836058 [TBL] [Abstract][Full Text] [Related]
11. Ondansetron: a new entity in emesis control. Graves T DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776 [TBL] [Abstract][Full Text] [Related]
13. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. Stewart DJ; Dahrouge S; Coyle D; Evans WK J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253 [TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114 [TBL] [Abstract][Full Text] [Related]
15. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552 [TBL] [Abstract][Full Text] [Related]
16. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
17. Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting. Kohler DR; Goldspiel BR DICP; 1991 Apr; 25(4):367-80. PubMed ID: 1833888 [TBL] [Abstract][Full Text] [Related]
18. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140 [TBL] [Abstract][Full Text] [Related]
19. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M; Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876 [TBL] [Abstract][Full Text] [Related]
20. The role of ondansetron in paediatric patients: a review of three studies. Stevens RF Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]